Olusegun Akinwale Ayeni

Olusegun Akinwale Ayeni

Auto-generated profile, based on publicly available information

Olusegun Akinwale Ayeni

Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMCarrie Anne Minnaar
Carrie Anne Minnaar
JKJeffrey Allan Kotzen
Jeffrey Allan Kotzen
OAOlusegun Akinwale Ayeni
Olusegun Akinwale Ayeni
TNThanushree Naidoo
Thanushree Naidoo
MTMariza Tunmer
Mariza Tunmer
ABAns Baeyens
Ans Baeyens
The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects of the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for the treatment of HIV-positive and -negative cervical cancer patients in a low-resource setting. This ongoing Phase III randomised controlled trial, conducted at a state hospital in Johannesburg, South Africa, was registered with the appropriate ethics committee. After signing an informed consent, participants with FIGO stages IIB to IIIB squamous cell carcinoma of the cervix were randomised to receive chemoradiotherapy with/without mEHT using a secure online random-sampling tool (stratum: HIV status) accounting for age and stage. Reporting physicians were blind to treatment allocation. HIV-positive participants on antiretroviral treatment, or with a CD4 count >200cell/μL were included. mEHT was administered 2/weekly immediately before external beam radiation. The primary end point is local disease control (LDC) and secondary endpoints are toxicity; quality of life analysis; and two year survival. We report on six month LDC, including nodes visualised in the radiation field on 18F-FDG PET/CT (censored for six month survival), and six month local disease free survival (LDFS) (based on intention to treat). Trial status: Recruitment closed (ClinicalTrials.gov: NCT03332069). 271 participants were recruited between January 2014 and November 2017, of which 210 were randomised for trial and 202 were available for analysis at six months post-treatment (mEHT: n = 101; Control: n = 101). Six month LDFS was higher in the mEHT Group (n = 39[38.6%]), than in the Control Group (n = 20[19.8%]); p = 0.003). LDC was also higher in the mEHT Group (n = 40[45.5%]) than the Control Group (n = 20[24.1%]); (p = 0.003). Our results show that mEHT is effective as a chemo-radiosensitiser for cervical cancer, even in high risk a patients and resource-constrained settings.

24 March 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CMCarrie Anne Minnaar
Carrie Anne Minnaar
JKJeffrey Allan Kotzen
Jeffrey Allan Kotzen
OAOlusegun Akinwale Ayeni
Olusegun Akinwale Ayeni
MVMboyo-Di-Tamba Vangu
Mboyo-Di-Tamba Vangu
ABAns Baeyens
Ans Baeyens
Background: A Phase III randomized controlled trial investigating the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced cervical cancer patients is being conducted in South Africa (Human Research Ethics Committee approval: M1704133; ClincialTrials.gov ID: NCT03332069). Two hundred and ten participants were randomized and 202 participants were eligible for six month local disease control evaluation. Screening 18F-FDG PET/CT scans were conducted and repeated at six months post-treatment. Significant improvement in local control was reported in the mEHT group and complete metabolic resolution (CMR) of extra-pelvic disease was noted in some participants. We report on an analysis of the participants with CMR of disease inside and outside the radiation field. Method: Participants were included in this analysis if nodes outside the treatment field (FDG-uptake SUV>2.5) were visualized on pre-treatment scans and if participants were evaluated by 18F-FDG PET/CT scans at six months post-treatment. Results: One hundred and eight participants (mEHT: HIV-positive n = 25, HIV-negative n = 29; Control Group: HIV-positive n = 26, HIV-negative n = 28) were eligible for analysis. There was a higher CMR of all disease inside and outside the radiation field in the mEHT Group: n = 13 [24.1%] than the control group: n = 3 [5.6%] (Chi squared, Fisher's exact: p = 0.013) with no significant difference in the extra-pelvic response to treatment between the HIV-positive and -negative participants of each group. Conclusion: The CMR of disease outside the radiation field at six months post-treatment provides evidence of an abscopal effect which was significantly associated with the addition of mEHT to treatment protocols. This finding is important as the combined synergistic use of radiotherapy with mEHT could broaden the scope of radiotherapy to include systemic disease.

1 April 2024 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
OKOlumayowa U. Kolade
Olumayowa U. Kolade
ABAnita Brink
Anita Brink
AAAkinwale O. Ayeni
Akinwale O. Ayeni
SMStuart More
Stuart More
JHJennifer Holness
Jennifer Holness
Background: PSMA PET/CT is the most sensitive molecular imaging modality for prostate cancer (PCa), yet much of the developing world has little or no access to PET/CT. [99mTc]Tc-PSMA scintigraphy (PS) is a cheaper and more accessible gamma camera-based alternative. However, many resource-constrained departments have only a single camera without tomographic or hybrid imaging functionality, and camera time is frequently in high demand. Simplifying imaging protocols by limiting the field of view (FOV) and omitting SPECT/CT or even SPECT may provide a partial solution. The aim was thus to determine the adequacy of PS planar-only and/or SPECT-only imaging protocols with a limited FOV. Methods: The scans of 95 patients with histologically proven PCa who underwent PS with full-body planar and multi-FOV SPECT/CT were reviewed. The detection rates for uptake in the prostate gland/bed and in metastases were compared on planar, SPECT, and SPECT/CT. The agreement between modalities was calculated for the detection of metastases and for staging. The impact of imaging a limited FOV was determined. Results: Pathological prostatic uptake was seen in all cases on SPECT/CT (excluding two post-prostatectomy patients), 90.3% of cases on SPECT, and 15.1% on planar images (p < 0.001). Eleven (11.7%) patients had seminal vesicle involvement on SPECT/CT, which was undetectable/indistinguishable on planar images and SPECT. The agreement between modalities was moderate to good (κ = 0.41 to 0.61) for the detection of nodal metastases, with detection rates that did not differ significantly (SPECT/CT = 11.6%, SPECT = 8.4%, planar = 5.3%). Detection rates for bone metastases were 14.7% (SPECT/CT) and 11.6% (SPECT and planar). Agreement between modalities for the detection of bone metastases was good (κ = 0.73 to 0.77). Three (3.1%) patients had visceral metastases on SPECT/CT, two of which were detected on SPECT and planar. There was good agreement between modalities for the TNM staging of patients (κ = 0.70 to 0.88). No metastatic lesions were missed on the limited FOV images. Conclusion: When PS scintigraphy is performed, SPECT/CT is recommended. However, the lack of SPECT/CT capabilities should not preclude the use of PS in the presence of limited resources, as both planar and SPECT imaging are adequate and will correctly stage most PCa patients. Furthermore, time-based optimisations are achievable by limiting the FOV to exclude the distal lower limbs.

1 January 2016
Verified
Open access
OAOlusegun Akinwale Ayeni
Olusegun Akinwale Ayeni
NMNico Malan
Nico Malan
EHEmmanuel Niiboye Hammond
Emmanuel Niiboye Hammond
MVMboyo-Di-Tamba Heben Vangu
Mboyo-Di-Tamba Heben Vangu
Dextrocardia is a cardiac positional anomaly in which the heart is located in the right hemithorax with its base-to-apex axis directed to the right and caudad. Situs inversus is an autosomal recessive disorder that causes organs in the chest and abdomen to be positioned in a mirror image from their normal position. Dextrocardia may occur in isolation or as part of situs inversus. Similarly, situs inversus may occur with or without dextrocardia. Situs inversus accompanied with dextrocardia (situs inversus totalis) is a rare congenital abnormality occurring in 0.01% of live births. Herein, we present the case of a 35-year-old man with previously diagnosed situs inversus totalis with mirror-image dextrocardia, referred to our facility for diagnosis of coronary artery disease (CAD). The incidence and presentation of CAD in patients with dextrocardia are similar to the normal population. However, considerable attention should be paid to the acquisition of myocardial perfusion scintigraphy and data processing/analysis in this group of patients. The present case highlights the distinctive applications and potential pitfalls of myocardial perfusion single-photon emission computed tomography (SPECT) imaging in patients with dextrocardia.

5 June 2014 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
JEJohn Enyi Ejeh
John Enyi Ejeh
TATolulope Hadrat Abiodun
Tolulope Hadrat Abiodun
KAKayode Solomon Adedapo
Kayode Solomon Adedapo
YOYetunde Ajoke Onimode
Yetunde Ajoke Onimode
OAOlusegun Akinwale Ayeni
Olusegun Akinwale Ayeni
The use of radionuclides in patients undergoing nuclear medicine procedures presents a special concern on the safety of not only the patients but also of those who come in contact with such patients either at the nuclear medicine centre or at home after discharge from the facility. This has heightened the public concern about nuclear medicine especially in Nigeria where the practice is new. When patients are injected with radioactivity for nuclear medicine procedures they excrete most of the radioactivity via urine even before leaving the nuclear medicine facility. Therefore, we set out to survey the toilets used by these patients in the hospital for radiation levels to know the radiation risk posed by the 'radioactive urine' of the patients to the general public and radiation workers respectively. A portable digital radiation survey meter was used for measurement of radioactivity in toilets used by a total number of 202 patients injected with 99mTc-based radiopharmaceuticals over a period of 60 days for the level of radioactivity. The minimum background radiation level measured was 0.18 µSv/h while the maximum was 0.44 µSv/h and the mean background reading was 0.28 µSv/h. The readings recorded for the male toilets were: 0.1 µSv/h minimum, 5.62 µSv/h maximum with a mean of 0.52 µSv/h while those for the female patients were 0.19 µSv/h minimum, 21.73 µSv/h maximum and a mean of 3.3 µSv/h. In conclusion, the radiation levels from toilets used by patients injected with 99mTc-based radiopharmaceuticals were within reasonable and acceptable limits and do not pose significant radiation risk to others.

1 December 2019 in Tomography
Verified
Journal Article
Open access
CMCarrie Anne Minnaar
Carrie Anne Minnaar
ABAns Baeyens
Ans Baeyens
OAOlusegun Akinwale Ayeni
Olusegun Akinwale Ayeni
JKJeffrey Allan Kotzen
Jeffrey Allan Kotzen
MVMboyo-Di-Tamba Vangu
Mboyo-Di-Tamba Vangu
Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in presentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging studies from women screened for a phase III randomised controlled trial investigating modulated electro-hyperthermia as a radiosensitiser (Ethics approval: M120477). The number of nodes; size; maximum standardised uptake value (SUVmax); symmetry; and relationship between nodal size and SUVmax uptake, were assessed by region and by HIV status. In total, 1314 nodes with a SUVmax ≥ 2.5 were visualised. Of 128(51%) HIV-positive participants, 82% were on antiretroviral therapy (ART) and 10 had a CD4 count four nodes visualised in the neck, symmetrical inguinal lymph nodes, increased rates of supraclavicular node visualisation; FDG-avid axillary nodes were more common, but not exclusive, in HIV-positive participants. 18F-FDG PET/CT is a reliable staging method for LACC in HIV-positive patients who are not in acute stages of HIV infection, have a CD4 count >200 cells/µL, and/or are on ART and there is a potential risk of underestimating metastatic spread by attributing increased nodal metabolic activity to HIV infection in these patients.